author-photo

Tillmann Taube

Boehringer Ingelheim

33

Papers

712

Citations

Citation Trend

Filter By

Papers (20) Sort By

Journal Conference Others

Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial

2021
Show All
- Source
- Cite
- Save
Citations (0)
Potential Drug-Drug Interactions with Combination Volasertib + Itraconazole: A Phase I, Fixed-Sequence Study in Patients with Solid Tumors.

2020 Clinical Therapeutics
Show All
- Source
- Cite
- Save
Citations (0)
Phase I dose-escalation study of volasertib in pediatric patients with acute leukemia or advanced solid tumors.

2019 Pediatric Blood & Cancer
Show All
- Source
- Cite
- Save
Citations (3)
Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with advanced solid tumors

2016 Investigational New Drugs
Show All
- Source
- Cite
- Save
Citations (12)
Phase I trial of volasertib, a Polo‐like kinase inhibitor, in Japanese patients with acute myeloid leukemia

2015 Cancer Science
Show All
- Source
- Cite
- Save
Citations (25)
A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies

2014 British Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (54)
Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy

2014 Blood
Show All
- Source
- Cite
- Save
Citations (171)
A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia.

2013 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (29)
Phase I/II Study of Volasertib (BI 6727), an Intravenous Polo-Like Kinase (Plk) Inhibitor, in Patients with Acute Myeloid Leukemia (AML): Results From the Randomized Phase II Part for Volasertib in Combination with Low-Dose Cytarabine (LDAC) Versus LDAC Monotherapy in Patients with Previously Untreated AML Ineligible for Intensive Treatment

2012 Blood
Show All
- Source
- Cite
- Save
Citations (21)
Procédé pour le traitement de tumeurs solides avancées

2012
Show All
- Source
- Cite
- Save
Citations (0)